AKERO THERAPEUTICS, INC.

AKRO US00973Y1082

🆔
Registration No.
6294543
💰
Capitalization
Mid-cap

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

🏢
Founded
2017
🔗
Website
https://www.akerotx.com
Annual Performance 1
2021 2022 2023 2024 2025
-15% 153% -53% 18% 1%
Annual Insiders Turnover, USD 2

1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);

Insider Activity
📊
Transactions
232
🙍
Insiders
9
Person Price Shares Total Published Completed
Young Jonathan
COO 		47.64
USD 		8,299
Sold 		395,398
USD 		01/10/2025 01/10/2025
Young Jonathan
COO 		47.64
USD 		8,299
Sold 		395,398
USD 		01/10/2025 01/10/2025
Young Jonathan
COO 		47.98
USD 		4,201
Sold 		201,581
USD 		01/10/2025 01/10/2025
Young Jonathan
COO 		47.64
USD 		8,299
Sold 		395,398
USD 		01/10/2025 01/10/2025
Young Jonathan
COO 		47.98
USD 		4,201
Sold 		201,581
USD 		01/10/2025 01/10/2025
Young Jonathan
COO 		47.64
USD 		8,299
Sold 		395,398
USD 		01/10/2025 01/10/2025
Yale Catriona
BDM 		43.02
USD 		659
Sold 		28,350
USD 		11/09/2025 11/09/2025
Cheng Andrew
CEO 		43.02
USD 		1,796
Sold 		77,264
USD 		10/09/2025 11/09/2025
Rolph Timothy
CSO 		43.02
USD 		553
Sold 		23,790
USD 		11/09/2025 11/09/2025
Young Jonathan
COO 		43.02
USD 		586
Sold 		25,210
USD 		11/09/2025 11/09/2025

Integrated EOD Stock Data and Insider Transactions Chart

Sign in or subscribe to include AKERO THERAPEUTICS, INC. to your watchlist and receive automatic alerts for upcoming transactions.

The visibility of insider buy and sell transactions on this chart should not be the sole factor in your decision to buy or sell a particular stock. Always consider the following dynamic reports for a broader understanding of stock market activities:

 

Historical Performance
1M 3M 6M 1Y 3Y 5Y All Time
-8% 5% 3% -49% -21% 0% 54%
Last 52W Low 52W High All-Time Low All-Time High β
46.49 21.87 57.56 8.00 57.56
Company Insiders
Person / Entity Transactions Turnover, USD Average, USD First Last
Cheng Andrew 50 25,560,165.34 511,203.31 07/12/2023 11/09/2025
Graham G. Walmsley 8 22,065,426.11 2,758,178.26 30/11/2023 27/03/2025
Yale Catriona 48 13,090,626.60 272,721.39 14/12/2023 11/09/2025
Young Jonathan 42 11,349,145.73 270,217.76 17/11/2023 01/10/2025
Rolph Timothy 36 8,833,913.90 245,386.50 14/12/2023 11/09/2025
White William Richard 20 8,515,843.83 425,792.19 14/12/2023 11/09/2025
Lamy Patrick 26 2,403,234.04 92,432.08 11/06/2024 01/07/2025
Henderson Jane 1 142,371.00 142,371.00 12/08/2025 12/08/2025
Gangloff Scott A. 1 46,504.32 46,504.32 18/06/2025 18/06/2025

Insiders marked in yellow represent long-term insiders. These are individuals who have engaged in transactions for over 3 years and have conducted at least 10 transactions or reached a cumulative turnover of $1M USD. When examining transaction clusters, we prioritize those conducted by long-term insiders for analysis.

Stock Advanced Metrics
Delta Correlation subscribe 🔒
Upper Bound of Standardized Transaction Amount (ubsta), USD 4 subscribe 🔒

4 represents the maximum expected transaction amount for a company's insiders, calculated based on historical data. It provides insight into the typical range of insider transaction amounts and helps in identifying unusually large transactions.

5 a proprietary metric reflecting the consistency of insider trading behavior within a company. A higher discipline index suggests more regular and predictable insider transactions.